Eli Lilly is betting $6.5 billion on a massive new Houston manufacturing facility as its obesity pill Foundayo grabs a fast-growing share of the booming GLP-1 market, and rival Novo Nordisk stumbles.
CEO Dave Ricks broke ground Monday at Generation Park, a roughly 240-acre site in Houston where Lilly plans to produce active ingredients for its small-molecule medicines. The plant is expected to be operational by 2030 and will serve drug programs across cardiometabolic health, oncology, immunology, and neuroscience. Ricks told CNBC in an exclusive interview that one-third of new GLP-1 pill patients are now taking Foundayo, and that the company's share of the oral market is growing week over week.
The numbers back up the confidence. Foundayo entered the U.S. market in April and booked $98 million in sales during its first full quarter. Lilly reported in August that it held roughly 61 percent of the overall GLP-1 market in the second quarter, a dominant position in a drug category that has reshaped how Americans treat obesity and diabetes.
Ricks kept his public message short and direct.
"We're confident long term."
That confidence is not just talk. Since 2020, Lilly has committed more than $50 billion to expanding its manufacturing network. In February 2025, the company pledged an additional $27 billion to build four new U.S. facilities, including the Houston site, an investment made in part to build goodwill with President Donald Trump as the administration pushes to reshore American pharmaceutical production.
While Ricks stood in front of the Houston construction site, Novo Nordisk was having a rough Monday. Shares of the Danish drugmaker fell after the company's long-term strategy failed to ease investor concerns about its ability to compete with Lilly. Novo had beaten Lilly to market with a GLP-1 pill, but that head start has not translated into dominance. Lilly's manufacturing scale and pipeline depth are proving harder to match than Novo anticipated.
The GLP-1 pill market matters because it represents the next frontier in obesity treatment. Injectable drugs like Zepbound and Wegovy opened the category, but pills are easier for patients to take and could dramatically expand the customer base. Lilly is positioning Foundayo as the pill that wins that race, and it is pouring billions into the factory capacity to back up the claim.
Lilly first announced the Houston facility nearly a year before the groundbreaking. The company chose Generation Park for its scale and proximity to the Gulf Coast's industrial infrastructure. At 240 acres, the site gives Lilly room to build out production lines that can keep pace with demand that shows no sign of slowing.
A major demand driver landed this summer when Medicare began landmark coverage of obesity drugs in July. That policy change is expected to open access to Foundayo and Zepbound for millions of older Americans who previously had to pay out of pocket or go without. For a company already capturing 61 percent of the GLP-1 market, Medicare coverage is an accelerant.
The coverage shift also raises questions about cost and access that go well beyond Lilly's balance sheet. New GLP-1 pills may push some employers to reconsider whether they can afford to cover these treatments at all, adding pressure to a benefits system already strained by rising drug prices.
Ricks told CNBC that Lilly plans to launch Foundayo in more international markets in the coming months, though he did not name specific countries. The international push would extend a drug that has already proven it can grab market share fast, $98 million in its first quarter on the U.S. market alone.
The scale of Lilly's investment is worth pausing on. More than $50 billion committed to manufacturing since 2020. Four new U.S. facilities announced in a single February pledge. A single plant in Houston worth $6.5 billion. These are not incremental bets. Lilly is building the physical infrastructure to dominate a drug category that barely existed a decade ago.
The company has also been aggressive in protecting its pipeline. Lilly recently sued six companies it accused of selling unapproved versions of one of its weight-loss compounds, a sign that the company sees counterfeit and gray-market drugs as a direct threat to its brand and its patients.
Meanwhile, the broader GLP-1 category continues to expand in unexpected directions. Scientists have launched clinical trials to test whether GLP-1 drugs can slow the aging process itself, a line of research that could open entirely new markets for companies like Lilly if the results hold up.
But the boom has not been without complications. Drug shortages remain a persistent problem across the pharmaceutical industry, and the FDA has continued adding drugs to its shortage list as American patients face growing gaps in basic medications. Lilly's massive manufacturing push is, in part, a direct response to the supply constraints that have plagued GLP-1 treatments since demand exploded.
Questions remain about how "new GLP-1 pill patients" are defined, whether that means patients new to GLP-1 treatment entirely or patients switching from injections to pills. The distinction matters because it shapes how large the addressable market really is. Recent research on GLP-1 dosing has also raised questions about efficacy at lower doses, adding another variable to the competitive picture.
Lilly's February commitment to build four new U.S. plants was made partly to align with the Trump administration's push to bring pharmaceutical manufacturing back to American soil. That is smart business and sound policy. The COVID-19 pandemic exposed how dangerously dependent the United States had become on foreign drug supply chains. Every major production facility built on U.S. soil is one less chokepoint a foreign government can exploit.
President Trump has made reshoring a centerpiece of his economic agenda, and companies like Lilly are responding with real capital, not press releases. A $27 billion commitment across four facilities is the kind of investment that creates jobs, strengthens supply chains, and keeps critical drug production under American jurisdiction.
Lilly is not spending $50 billion because it expects the GLP-1 market to flatten. It is spending because it expects the market to grow, and because the company that builds the factories first will be the one that sets the terms. Washington should take note: when the incentives are right, American companies will invest at home. The job is to keep those incentives pointed in the right direction.